 Zacks Investment Research upgraded shares of Adaptimmune Therapeutics NASDAQ:ADAP from a hold rating to a buy rating in a report released on Tuesday morning, Zacks.com reports. Zacks Investment Research currently has 10.00 price objective on the biotechnology companys stock. According to Zacks, Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer ... 